Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study

Ulrich Gerckens[1]*, Corrado Tamburino[2], Sabine Bleiziffer[3], Johan Bosmans[4], Peter Wenaweser[5], Stephen Brecker[6], Jia Guo[7], and Axel Linke[8]

[1]Department of Cardiology, University of Rostock, Ernst-Heydemann- Straße, 618057 Rostock, Germany; [2]Cardiology Unit, Ferrarotto Hospital, University of Catania, Via Salvatore Citelli, 6, 95124 Catania CT, Italy; [3]Department of Cardiovascular Surgery, German Heart Centre, Lazarettstraße 36, 80636 Munich, Germany; [4]Cardiovascular Diseases Department, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium; [5]Department of Cardiology, University Hospital Bern, Freiburgstrasse 8, 3010 Bern, Switzerland; [6]Cardiology Clinical Academic Group, St. George's Hospital, Blackshaw Rd, London SW17 0QT, UK; [7]Coronary and Structural Heart, Medtronic, 8200 Coral Sea Street NE, Mounds View, MN 55112 USA; and [8]Department of Internal Medicine and Cardiology, University of Leipzig Heart Centre, Strümpellstraße 39, 04289 Leipzig, Germany

Aims	The ADVANCE study was designed to evaluate the safety and effectiveness of transcatheter aortic valve implantation (TAVI) with a self-expanding bioprosthesis in real-world patients with symptomatic, severe aortic stenosis at high surgical risk for valve replacement.
Methods and results	Study participants were enrolled from 44 experienced centres in 12 countries. Patient eligibility, treatment approach, and choice of anaesthesia were determined by the local Heart Team. The study was 100% monitored, and adverse events were adjudicated by an independent clinical events committee using Valve Academic Research Consortium (VARC-1) criteria. There were 1015 patients enrolled with 996 attempted TAVI procedures. Mean age was 81 years, and mean logistic EuroSCORE was 19.3 ± 12.3%. Five-year follow-up was available on 465 (46.7%) patients. At 5 years, the rate of all-cause mortality was 50.7% (95% confidence interval: 46.7%, 54.5%), and the rate of major stroke was 5.4%. Haemodynamic measures remained consistent for paired patients with a mean aortic valve gradient of 8.8 ± 4.4 mmHg ($n = 198$) and an effective orifice area of 1.7 ± 0.4 cm^2 ($n = 123$). Aortic regurgitation (AR) decreased over time and among paired patients dropped from 12.8% to 8.0% moderate AR at 5 years ($n = 125$). Of the 860 patients with echocardiographic data or a reintervention after 30 days, there were 22 (2.6%) patients meeting the VARC-2 criteria for valve dysfunction and 10 (1.2%) patients with a reintervention >30 days.
Conclusion	Five-year results in real-world, elderly, high-risk patients undergoing TAVI with a self-expanding bioprosthesis provided evidence for continued valve durability with low rates of reinterventions and haemodynamic valve dysfunction.
Trial registration	ClinicalTrials.gov, NCT01074658.
Keywords	Transcatheter aortic valve implantation • Aortic valve durability • CoreValve • Aortic stenosis

* Corresponding author. Tel: +49 173 672 0513, Fax: +49 228 258007, Email: gerckensu@gmail.com

Introduction

Short-term safety and efficacy of transcatheter aortic valve implantation (TAVI) in symptomatic severe aortic stenosis patients at high and extreme risk for surgery has been established in several prospective clinical trials.[1–4] More recently, TAVI has been shown to be non-inferior to surgical valve replacement in symptomatic patients, deemed intermediate risk for surgical intervention,[5,6] and data from one randomized, clinical trial have demonstrated similar safety and efficacy to surgery in low-risk patients with symptomatic severe aortic stenosis.[7] As adoption of TAVI expands into younger and lower risk patients, longer term clinical outcomes and bioprosthetic valve durability are of increasing importance. Although clinical outcomes through 3 to 5 years from multiple randomized clinical trials[8–10] provide evidence for the safety of TAVI in higher risk patients, questions regarding bioprosthetic valve durability remain a concern.[11–13]

The CoreValve ADVANCE study is a prospective, global multicentre observational clinical study that evaluated the self-expanding CoreValve bioprosthesis for TAVI in a real-world population. Unlike other large registries that may have under-reported adverse events, the ADVANCE study was fully monitored, and all events were independently adjudicated. Complete 5-year clinical and echocardiographic data are now available. Additional *post hoc* analyses were conducted to evaluate bioprosthetic valve durability through 5 years and factors impacting mortality.

Methods

Patients and study design

Patient selection and design of the ADVANCE study have been previously described.[14] Briefly, ADVANCE is a global, prospective, non-randomized, multicentre clinical study that enrolled real-world patients with symptomatic, severe aortic valve stenosis suitable for TAVI. Participants were enrolled at 44 centres from 12 countries; all centres were required to have TAVI experience of at least 40 cases. Each centre was also required to have a Heart Team comprised of at least one TAVI-experienced interventional cardiologist and one cardiothoracic surgeon to evaluate patient suitability for TAVI. The ADVANCE study complied with the Declaration of Helsinki, with approval of the research protocol from all locally appointed ethics committees, and informed consent was obtained from all patients or their legally authorized representative. Description of the CoreValve bioprosthesis and corresponding implant details have been presented previously.[15,16] CoreValve sizes of 26 and 29 mm were available during the ADVANCE study to treat aortic valve annulus sizes from 20 mm to 27 mm. Each centre's Heart Team determined the access route (iliofemoral, direct aortic, or subclavian) and type of anaesthesia (general or conscious sedation) for each patient. Follow-up visits were scheduled at 30 days and then annually up to 5 years.

The primary endpoint of the ADVANCE study was major adverse cardiac and cerebrovascular events at 30 days post-procedure, defined as a composite of all-cause mortality, myocardial infarction, stroke, or reintervention. Additional clinical endpoints included cardiovascular mortality, vascular complications, major and minor stroke, and new pacemaker implantation. The study was fully monitored, and adverse events were adjudicated by an independent clinical events committee comprised of interventional cardiologists and cardiac surgeons using definitions from Valve Academic Research Consortium (VARC-1).[17] The committee reviewed patient source data as well as assessments from an independent neurologist to adjudicate all events.

Echocardiographic analysis

Echocardiographic data are reported by each investigative centre. Mean gradient; effective orifice area (EOA); and total and paravalvular aortic regurgitation (AR) data at baseline, discharge, 1 month, and annually to 5 years were analysed.

Prosthetic valve durability analysis

Prosthetic valve durability was assessed *post hoc* using echocardiographic data and VARC-2 definitions.[18] This analysis used the last available echo post 30 days after implantation or the last echo before a reintervention greater than 30 days post-procedure; only patients who had an echo in at least one of these categories were included in the analysis. Surgical criteria for aortic valve stenosis was defined as a greater than 50% increase of mean gradient from 1 month to 5 years.[19] VARC-2 criteria for aortic valve stenosis was defined as: [(aortic valve mean gradient ≥20 mmHg or peak velocity ≥3 m/s) and (EOA ≤0.9 cm^2 if body surface area is <1.6 or ≤1.1 cm^2 if body surface area is ≥1.6)] or moderate to severe total AR.[18] Structural aortic valve deterioration, defined as valve dysfunction or deterioration, exclusive of infection or thrombosis, as determined by reoperation, autopsy, or clinical investigation was also collected during the study. Specifically, this included changes intrinsic to the valve, such as wear, fracture, calcification, leaflet tear, stent creep, or suture line disruption of components of a trial valve as site reported.

Statistical analysis

Continuous variables are reported as the mean ± standard deviation. Categorical variables are reported as the number and percentage. Clinical outcomes were calculated using Kaplan–Meier survival analysis, and freedom from mortality curves were also generated using Kaplan–Meier methods. The log-rank test was used to test for differences across and between groups. For subjects without an event, the date of censoring was the latest date of all follow-up visits (including study exit) and events (including death). Predictors of mortality at 5 years were evaluated using univariable and stepwise multivariable Cox regression models with an entry *P*-value of 0.1 and a stay *P*-value of 0.05. Hazard ratios with two-sided 95% confidence interval (CIs) were calculated. All tests were two sided. All analyses were performed using SAS software (Cary, NC, USA), version 9.2 or above.

Results

Patient and procedural characteristics

Baseline characteristics and procedural data for patients enrolled in ADVANCE have been described previously.[14] In brief, from March 2010 to July 2011, 1015 patients were enrolled and TAVI procedures were attempted in 996 patients; 49.3% of patients were male, mean age was 81 years, 80.0% were in NYHA Class III or IV, the mean STS score was 6.4 ± 4.4%, and the mean logistic EuroSCORE was 19.3 ± 12.3%. Additional baseline characteristics can be found in Supplementary material online, *Table S1*. For TAVI procedures, iliofemoral access was used in 88.4% of patients, subclavian access in 9.5% and 2.1% had direct aortic access.[14] Balloon valvuloplasty was performed pre-procedure in 91.0% of patients and post-procedure in 23.6%.[14] Five-year follow-up is available for 465 of 506 (91.9%) patients with attempted implant. There were 25 patient withdrawals,

Table 1 Clinical outcomes at 1 and 5 years (n = 996)

	1 Year		5 Years	
	% (n)	95% CI	% (n)	95% CI
All-cause mortality[a]	17.6 (174)	[15.3, 20.1]	50.7 (489)	[46.7%, 54.5%]
Cardiovascular mortality	11.6 (112)	[9.7, 13.8]	33.5 (289)	[29.3%, 37.8%]
All-cause mortality or major stroke	18.1 (179)	[15.8, 20.6]	51.8 (501)	[47.9%, 55.6%]
Stroke[a]	4.4 (42)	[3.2, 6.0]	10.2 (78)	[7.2%, 13.7%]
Major stroke	2.1 (20)	[1.3, 3.3]	5.4 (41)	[3.3%, 8.2%]
Minor stroke	2.3 (22)	[1.4, 3.5]	5.3 (40)	[3.2%, 8.1%]
Transient ischaemic attack	1.7 (15)	[0.9, 2.7]	2.6 (21)	[1.2%, 4.8%]
Myocardial infarction[a]	0.9 (8)	[0.4, 1.8]	3.7 (27)	[2.0, 6.1]
New pacemaker implantation	29.1 (284)	[26.0, 32.3]	33.7 (312)	[28.4, 39.0]
Emergent cardiac surgery or percutaneous reintervention[a]	1.6 (15)	[0.9, 2.6]	2.8 (23)	[1.4, 5.0]
Acute kidney injury (all 3 stages)	6.6 (64)	[5.0, 8.4]	10.1 (87)	[7.1, 13.6]
Life-threatening or disabling bleeding	4.9 (48)	[3.6, 6.5]	6.2 (57)	[3.9, 9.2]
Structural valve deterioration[b]	0.2 (2)	[0.0, 0.8]	0.9 (6)	[0.2, 2.5]
Major adverse cardiac and cerebrovascular events	21.0 (208)	[18.5, 23.6]	55.8 (541)	[51.9, 59.5]

Data presented as Kaplan–Meier estimates of outcomes in the attempted implant study cohort.
[a]Components which comprise major adverse cardiac and cerebrovascular events.
[b]Structural valve deterioration includes trial valve dysfunction or deterioration, exclusive of infection or thrombosis, as determined by reoperation, autopsy, or clinical investigation. The term refers to changes intrinsic to the valve, such as wear, fracture, calcification, leaflet tear, stent creep, or suture line disruption of components of a trial valve.

16 lost to follow-up and 490 patient deaths over 5 years (see Supplementary material online, *Figure S1*).

Clinical outcomes and predictors of mortality

Clinical outcomes at 1 and 5 years are shown in *Table 1*. At 5 years, the rate of all-cause mortality was 50.7%, all-cause mortality or major stroke was 51.8%, and cardiovascular mortality was 33.5% (*Figure 1A*). The rate of stroke at 5 years was 10.2% with approximately half ajudicated as major stroke (5.4%) (*Figure 1B*).

The rate of new pacemaker implantation within 30 days post-TAVI was 33.7% at 5 years but was not associated with an increase in mortality (*Figure 2A*). When rates of freedom from all-cause mortality were stratified by EuroSCORE the highest baseline EuroSCORE was associated with the worst survival through 5 years (*Figure 2B*). The impact of discharge AR is shown in *Figure 2C*. Moderate or severe AR was associated with the lowest survival (45.2% at 5 years). There also appears to be an impact of mild AR on mortality demonstrated only after 2 years with a rate of 50.7% at 5 years. NYHA classification for 320 patients who were assessed at all time points of baseline, 1 month, and annually to 5 years indicated a gradual increase in Class III symptoms during Years 3 through 5, but the majority of patients remained Class I or II (80.9%) (see Supplementary material online, *Figure S2*).

Multivariable predictors of mortality through 5 years are shown in *Figure 3*; complete univariable and multivariable predictors are found in Supplementary material online, *Table S2*. Multivariable predictors of mortality were age, presence of peripheral vascular disease, chronic obstructive lung disease, elevated serum creatinine, baseline left ventricular ejection fraction ≤50%, major bleeding and Stage 3 acute kidney injury. Higher baseline mean aortic valve gradient was associated with lower mortality.

Echocardiographic measures

Echo compliance decreased over time with a follow-up rate of 67% at Years 3 and 4 and 56% at 5 years. There were 125 patients with AR measurements at baseline and all follow-up time points (discharge, 1 month, and annually to 5 years). At 5 years, 40.8% of these paired patients had no AR, compared with 21.6% at discharge. Degree of moderate AR went from 12.8% at discharge to 8.0% at 5 years, and no patients had severe AR from discharge to 5 years, inclusively (*Figure 4A*). Similarly, *Figure 4B* shows AR for all patients, including a category for patients who were deceased or had a missed visit. Mean aortic valve effective orifice area and mean gradient from baseline to 5 years are shown in *Figure 5*. In patients with data at baseline and 5 years mean gradient dropped from 45.3 ± 15.9 at baseline to 9.8 ± 4.4 mmHg at discharge and 8.8 ± 4.4 mm Hg at 5 years (n = 198). Mean gradient measurements for all available patients vs. patients with echocardiographic follow-up at all time points are shown in Supplementary material online, *Table S3*. Mean EOA for paired patients was 0.8 ± 0.5 at baseline and 1.7 ± 0.4 cm^2 at 5 years (n = 123).

Prosthetic valve durability

The incidence of structural valve deterioration was site reported as 0.9% at 5 years. Additional *post hoc* analysis on durability of the CoreValve bioprosthesis was analysed in 860 patients (*Table 2*). Mean follow-up time was 36.0 ± 21.1 months, and 267 patients had follow-up through 5 years. There was a >50% increase in baseline mean gradient in 9.3% of patients and the rate of valve dysfunction per VARC-2 criteria was 2.6% (n = 22) at 5 years of follow-up. Two of the 22 patients meeting criteria for aortic valve stenosis also had a reintervention, 10 patients had a high mean gradient or peak velocity, 11 patients had moderate or severe AR, and 1 patient had a high mean gradient and peak velocity plus moderate AR (*Figure 6*).

Figure 1 Kaplan–Meier time to event analyses for select clinical endpoints. (*A*) Freedom from all-cause mortality through 5 years; (*B*) Freedom from all stroke, major stroke, minor stroke, and transient ischaemic attacks per VARC-1 definitions.[16]

Ten (1.2%) patients had reinterventions after 30 days post-procedure, where 4 procedures were surgical reinterventions and 6 were percutaneous. For these 10 reinterventions, 2 were caused by prosthetic degeneration and subsequent aortic stenosis. Additional details on the patients and their reintervention procedures are found in Supplementary material online, *Table S4*.

Of the 996 patients, 1.8% (18 patients) were diagnosed with endocarditis, where 2 patients had 2 occurrences each of endocarditis. Thirty-five per cent of cases were related to the prosthetic valve and 4 cases occurred within 6 months of the procedure. Three patients died due to endocarditis.

Discussion

The CoreValve ADVANCE clinical study provides longer term data on a large, real-world international population of TAVI patients.[14,20,21] The 5-year results from ADVANCE continue to demonstrate the strong haemodynamic performance of the CoreValve bioprosthesis, as well as low rates of stroke, AR, and a 5-year mortality rate within the expected range for this elderly TAVI population.

As the first TAVI procedure was performed just 15 years ago, to date, there are only a few multicentre clinical studies with reported results from 5 years of follow-up.[9,13,22] All-cause mortality for patients in the CoreValve ADVANCE study was 50.7% (95% CI: 46.7%, 54.5%) at 5 years, similar to results described by Barbanti [55% (95% CI: 49–60%)][13] and Duncan (54.5%).[22] PARTNER 1, a randomized controlled trial of TAVI vs. surgical implantation, reported all-cause mortality of 67.8% at 5 years,[9] higher than ADVANCE, potentially due to differences in study design and baseline risk of enrolled patients (STS score of 10.7 ± 3.5% for PARTNER 1 vs. 6.4 ± 4.4% for ADVANCE). Likewise, cardiovascular mortality was 33.5% at 5 years in ADVANCE and 53.1% for PARTNER 1.[9] Barbanti *et al.*[13] reported

Figure 2 Kaplan–Meier time-to-event analyses for all-cause mortality stratified by: (*A*) the presence of an existing pacemaker prior to TAVI, the need for a new pacemaker, and no pacemaker; (*B*) logistic EuroSCORE (≤10%, >10–20%, and >20%); (*C*) aortic regurgitation (none, mild, and moderate or severe).

Variable	Hazard Ratio (95% CI)	p-Value
Age (years)	1.03 (1.01, 1.05)	<0.001
Peripheral vascular disease	1.43 (1.11, 1.84)	0.006
Chronic obstructive pulmonary disease	1.32 (1.03, 1.70)	0.03
Creatinine (mg/dL)	1.22 (1.11, 1.35)	<0.001
Baseline LVEF ≤ 50%	1.37 (1.09, 1.72)	0.008
Baseline mean AV gradient	0.99 (0.98, 1.00)	0.029
Major bleeding	1.58 (1.19, 2.09)	0.001
Acute kidney injury (stage III)	14.31 (5.72, 35.79)	<0.001

Figure 3 Forest plot for multivariable analysis of predictors of all-cause mortality through 5 years.

Figure 4 Aortic regurgitation through 5 years: (*A*) for patients with available data at all follow-up time points and (*B*) for all patients accounting for those missing or dead.

Figure 5 Haemodynamic measures from baseline through 5 years. Effective orifice area is shown in blue and mean gradient is shown in orange.

Table 2 Prosthetic valve durability

Characteristic	n = 860
Mean follow-up (months)	36.0 ± 21.1
First and third quartile of follow-up time (months)	[13.5, 59.3]
Reintervention after 30 days	10 (1.2%)
Surgical criteria for aortic valve stenosis[a]	80 (9.3%)
VARC-2[b] criteria for aortic valve stenosis[c]	22 (2.6%)
Reintervention after 30 days or VARC-2 criteria	30 (3.5%)

VARC, Valve Academic Research Consortium; AV, aortic valve; EOA, effective orifice area; BSA, body surface area.
[a]>50% increase of mean gradient from 1 month to 5 years.
[b]The analysis set included subjects with at least 1 echo post 30 day or reintervention >30 days; 267 patients had follow-up at 5 years.
[c]VARC-2 definition: (AV mean gradient ≥20 mmHg or peak velocity ≥3 m/s) and (EOA ≤0.9 cm^2 if BSA <1.6 or ≤ 1.1 cm^2 if BSA ≥1.6) or (≥moderate/severe total aortic regurgitation).

cardiovascular mortality of 28% at 5 years in a large Italian registry, similar to ADVANCE.

There are limited data on rate of stroke at 5 years post-TAVI. The rate of stroke at 5 years in ADVANCE was 10.2%, similar to the rate of 10.4% in PARTNER 1.[9] The Italian registry reported a 5-year stroke rate of 7.5%.[13] A number of clinical studies have described an early incidence of strokes post-TAVI, followed by lower rates of stroke over time.[13,23] Similarly, in ADVANCE, the stroke rate at 30 days post-TAVI was 3.0%, and increased at a much slower rate after that to 5 years.

The observed continued improvement in AR over time for paired patients followed through 5 years are confirming of the findings from the US CoreValve Pivotal Trial[8] and may be related to continued valve frame expansion or tissue ingrowth over time.

An evaluation of surgical bioprosthetic valve explants suggests that an increase in mean gradient of >50% over discharge may correlate with valve thrombosis.[19] A recent presentation further showed an association between subclinical leaflet thrombosis and a higher rate of transient ischemic attacks.[24] There was no measure of valve thrombosis in ADVANCE; however, 9.3% of patients had a 50% or more increase in mean gradient. Additional clinical studies are ongoing to further assess the relationship between leaflet immobility, subclinical thrombosis, and clinical outcomes.

In ADVANCE, we identify a low rate of reinterventions after 30 days that is consistent with reports from other studies. There were 2 cases (0.6%) with aortic valve reintervensions with the CoreValve bioprosthesis in the Italian registry; both were valve-in-valve TAVI procedures occurring between 4 and 5 years.[13] Moreover, there were 3 patients with prosthetic dysfunction who did not undergo reintervention: 1 case of endocarditis, 1 case of asymptomatic valve degeneration with severe AR and 1 case of worsening (moderate-to-severe) paravalvular regurgitation. Three-year follow-up of the CoreValve High-Risk US pivotal trial reported a reintervention rate of 2.5% in patients receiving TAVI but noted that the majority of these events occurred before 30 days.[8] Although 22 patients in ADVANCE met VARC-2 criteria for aortic stenosis, only 2 had reinterventions. The low rate of reintervention and aortic valve stenosis assessed after 30 days provides reassuring data regarding the durability of the self-expanding CoreValve through 5 years.

Figure 6 The number of patients meeting criteria for valve dysfunction per VARC-2 criteria classified by criteria met: patients with an aortic valve gradient ≥20 mmHg are shown in blue, patients with a mean gradient <20 mmHg but with a peak velocity ≥3 m/s are shown in green and patients with moderate or severe aortic regurgitation are shown in orange.

Predictors of mortality through 5 years were consistent with those identified at 1 year.[14] Peripheral vascular disease, elevated serum creatinine, low ejection fraction, and acute kidney injury remained as predictors and as expected, greater age is associated with a higher risk for mortality through 5 years. When freedom from mortality was stratified by degree of AR, we noted lower rates of survival for patients with moderate/severe and mild AR (detectable after 2 years) at discharge, suggesting that AR may contribute to higher mortality over time. The FRANCE-2 Registry, which enrolled over 3000 patients, found that moderate-to-severe post-procedural AR was the strongest independent predictor of 1-year mortality.[25] Patients who received a new pacemaker within 30 days post-procedure had similar 5-year survival to patients with an existing pacemaker or no pacemaker (log-rank $P = 0.48$). This is consistent with previous CoreValve clinical studies that did not find any increase in mortality between patients with and without a new pacemaker.[7,26]

There are several limitations in our analysis. Echo visit compliance at 5 years was only 56% and assessment of haemodynamic valve function overtime may underestimate the rate of valve dysfunction at 5 years. It is possible that patients who died during the study duration without a recent echo may have had undiagnosed valve deterioration, but the available echo data argue against a premature valve deterioration. It is likely that some patients with AR died earlier in the study, which affects the proportion of patients with mild or greater AR at 5 years. Nevertheless, the paired echo data indicates that AR is improving over time. In addition, echo measurements were site reported, as there was no echo core lab adjudication for this study.

The 5-year results from the ADVANCE clinical study demonstrated consistent low mean aortic valve gradients associated with the self-expanding CoreValve and provide insights into longer term clinical outcomes for 'real-world' TAVI patients. Analysis of bioprosthetic valve durability through 5 years further demonstrated low rates of reinterventions and haemodynamic valve dysfunction. As the use of TAVI moves into lower risk, younger patients continued follow-up will be essential to reassure physicians and patients of the long-term safety of TAVI.

Supplementary material

Supplementary material is available at *European Heart Journal* online.

References

1. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK; U.S. CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014;**370**:1790–1798.

2. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010;**363**:1597–1607.

3. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, Thourani VH, Babaliaros VC, Webb JG, Herrmann HC, Bavaria JE, Kodali S, Brown DL, Bowers B, Dewey TM, Svensson LG, Tuzcu M, Moses JW, Williams MR, Siegel RJ, Akin JJ, Anderson WN, Pocock S, Smith CR, Leon MB; PARTNER Trial Investigators. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. *N Engl J Med* 2012;**366**:1696–1704.

4. Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D, Hermiller J Jr, Hughes GC, Harrison JK, Coselli J, Diez J, Kafi A, Schreiber T, Gleason TG, Conte J, Buchbinder M, Deeb GM, Carabello B, Serruys PW, Chenoweth S, Oh JK; CoreValve United States Clinical Investigators. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. *J Am Coll Cardiol* 2014;**63**:1972–1981.

5. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW, Kappetein AP; SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. *N Engl J Med* 2017;**376**:1321–1331.

6. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG; PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N Engl J Med* 2016;**374**:1609–1620.

7. Sondergaard L, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, Ngo AT, Olsen NT, Chang Y, Franzen OW, Engstrom T, Clemmensen P, Olsen PS, Thyregod HG. Two-Year outcomes in patients with severe aortic valve stenosis randomized to transcatheter versus surgical aortic valve replacement: the all-comers Nordic aortic valve intervention randomized clinical trial. *Circ Cardiovasc Interv* 2016;**9**:e003665. doi: 10.1161/CIRCINTERVENTIONS.115.003665.

8. Deeb GM, Reardon MJ, Chetcuti S, Patel HJ, Grossman PM, Yakubov SJ, Kleiman NS, Coselli JS, Gleason TG, Lee JS, Hermiller JB Jr, Heiser J, Merhi W, Zorn GLIII, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Maini B, Mumtaz M, Conte J, Resar J, Aharonian V, Pfeffer T, Oh JK, Qiao H, Adams DH, Popma JJ; CoreValve U.S. Clinical Investigators. Three-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. *J Am Coll Cardiol* 2016;**67**:2565–2574.

9. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, Webb JG, Douglas PS, Anderson WN, Blackstone EH, Kodali SK, Makkar RR, Fontana GP, Kapadia S, Bavaria J, Hahn RT, Thourani VH, Babaliaros V, Pichard A, Herrmann HC, Brown DL, Williams M, Akin JJ, Davidson MJ, Svensson LG; PARTNER Trial Investigators. 5-Year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet* 2015;**385**:2477–2484.

10. Kapadia SR, Tuzcu EM, Makkar RR, Svensson LG, Agarwal S, Kodali S, Fontana GP, Webb JG, Mack M, Thourani VH, Babaliaros VC, Herrmann HC, Szeto W, Pichard AD, Williams MR, Anderson WN, Akin JJ, Miller DC, Smith CR, Leon MB. Long-term outcomes of inoperable patients with aortic stenosis randomized to transcatheter aortic valve replacement or standard therapy. *Circulation* 2014;**130**:1483–1492.

11. Sondergaard L. Time to explore transcatheter aortic valve replacement in younger, low-risk patients. *JACC Cardiovasc Interv* 2016;**9**:2183–2185.

12. Joint Task Force on the Management of Valvular Heart Disease of the European Society of (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J* 2012;**33**:2451–2496.

13. Barbanti M, Petronio AS, Ettori F, Latib A, Bedogni F, De Marco F, Poli A, Boschetti C, De Carlo M, Fiorina C, Colombo A, Brambilla N, Bruschi G, Martina P, Pandolfi C, Giannini C, Curello S, Sgroi C, Gulino S, Patane M, Ohno Y, Tamburino C, Attizzani GF, Imme S, Gentili A, Tamburino C. 5-Year outcomes after transcatheter aortic valve implantation with CoreValve prosthesis. *JACC Cardiovasc Interv* 2015;**8**:1084–1091.

14. Linke A, Wenaweser P, Gerckens U, Tamburino C, Bosmans J, Bleiziffer S, Blackman D, Schafer U, Muller R, Sievert H, Sondergaard L, Klugmann S, Hoffmann R, Tchetche D, Colombo A, Legrand VM, Bedogni F, lePrince P, Schuler G, Mazzitelli D, Eftychiou C, Frerker C, Boekstegers P, Windecker S, Mohr FW, Woitek F, Lange R, Bauernschmitt R, Brecker S; ADVANCE Study Investigators. Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study. *Eur Heart J* 2014;**35**:2672–2684.

15. Grube E, Schuler G, Buellesfeld L, Gerckens U, Linke A, Wenaweser P, Sauren B, Mohr FW, Walther T, Zickmann B, Iversen S, Felderhoff T, Cartier R, Bonan R. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. *J Am Coll Cardiol* 2007;**50**:69–76.

16. Piazza N, Grube E, Gerckens U, den Heijer P, Linke A, Luha O, Ramondo A, Ussia G, Wenaweser P, Windecker S, Laborde JC, de Jaegere P, Serruys PW. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. *EuroIntervention* 2008;**4**:242–249.

17. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. *J Am Coll Cardiol* 2011;**57**:253–269.

18. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodes-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 consensus document. *Eur Heart J* 2012;**33**:2403–2418.

19. Egbe AC, Pislaru SV, Pellikka PA, Poterucha JT, Schaff HV, Maleszewski JJ, Connolly HM. Bioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic predictors. *J Am Coll Cardiol* 2015;**66**:2285–2294.

20. Bosmans J, Bleiziffer S, Gerckens U, Wenaweser P, Brecker S, Tamburino C, Linke A; ADVANCE Study Investigators. The incidence and predictors of early- and mid-term clinically relevant neurological events after transcatheter aortic valve replacement in real-world patients. *J Am Coll Cardiol* 2015;**66**:209–217.

21. Brecker SJ, Bleiziffer S, Bosmans J, Gerckens U, Tamburino C, Wenaweser P, Linke A; ADVANCE Study Investigators. Impact of anesthesia type on outcomes of transcatheter aortic valve implantation (from the Multicenter ADVANCE Study). *Am J Cardiol* 2016;**117**:1332–1338.

22. Duncan A, Ludman P, Banya W, Cunningham D, Marlee D, Davies S, Mullen M, Kovac J, Spyt T, Moat N. Long-term outcomes after transcatheter aortic valve replacement in high-risk patients with severe aortic stenosis: the U.K. Transcatheter Aortic Valve Implantation Registry. *JACC Cardiovasc Interv* 2015;**8**:645–653.

23. Kleiman NS, Maini BJ, Reardon MJ, Conte J, Katz S, Rajagopal V, Kauten J, Hartman A, McKay R, Hagberg R, Huang J, Popma J, CoreValve I. Neurological events following transcatheter aortic valve replacement and their predictors: a report from the CoreValve trials. *Circ Cardiovasc Interv* 2016;**9**:e003551. doi: 10.1161/CIRCINTERVENTIONS.115.003551.

24. Makkar R. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic aortic valves: results from RESOLVE and SAVORY registries. *Paper presented at:* 66th Annual Scientific Session of the American College of Cardiology; March 19, 2017; Washington, DC.

25. Van Belle E, Juthier F, Susen S, Vincentelli A, Iung B, Dallongeville J, Eltchaninoff H, Laskar M, Leprince P, Lievre M, Banfi C, Auffray JL, Delhaye C, Donzeau-Gouge P, Chevreul K, Fajadet J, Leguerrier A, Prat A, Gilard M, Teiger E; FRANCE Investigators. Postprocedural aortic regurgitation in balloon-expandable and self-expandable transcatheter aortic valve replacement procedures: analysis of predictors and impact on long-term mortality: insights from the FRANCE2 Registry. *Circulation* 2014;**129**:1415–1427.

26. Yakubov SJ, Adams DH, Watson DR, Reardon MJ, Kleiman NS, Heimansohn D, Hermiller J Jr, Hughes GC, Harrison JK, Coselli J, Diez J, Schreiber T, Gleason TG, Conte J, Deeb GM, Huang J, Oh J, Byrne T, Caskey M, Popma JJ; CoreValve United States Clinical I. 2-year outcomes after iliofemoral self-expanding transcatheter aortic valve replacement in patients with severe aortic stenosis deemed extreme risk for surgery. *J Am Coll Cardiol* 2015;**66**: 1327–1334.